Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia - Wikidata - wikimedia - TriplyDB

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

http://www.wikidata.org/entity/Q34069284

about

α-Synuclein modifies huntingtin aggregation in living cells Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein The protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathway Alpha-synuclein and tau: teammates in neurodegeneration?Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia Phosphorylation of NBR1 by GSK3 modulates protein aggregation.Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy.Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.From model system to clinical medicine: pathophysiologic links of common proteinopathies.Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.GSK-3 in Neurodegenerative Diseases.CSF biomarkers and clinical progression of Parkinson disease.α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson's Disease Low doses of single or combined agrichemicals induces α-synuclein aggregation in nigrostriatal system of mice through inhibition of proteasomal and autophagic pathways.Parkinson disease and progressive supranuclear palsy: protein expression in skin.Combining Dopaminergic Facilitation with Robot-Assisted Upper Limb Therapy in Stroke Survivors: A Focused Review Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Gsk3β and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson's disease.Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.Interaction between pathogenic proteins in neurodegenerative disorders.

P2860

Q24298430-3A57E00F-BE5E-4E51-81D7-07902FBA8128 Q26744782-6010741E-FB80-4B8E-9E89-2AB5A4500D3D Q26853610-B93F075A-3700-4DC9-9BF1-8582AD4B3DCA Q27304608-7BB02DB3-7C66-4421-ADC6-1EED6324A270 Q27330366-53C46622-FE19-4183-BCE8-8F3772DC9074 Q27331743-5300F2CA-A46D-4137-A528-1E252A8802B9 Q28117215-8B4F1245-ABDC-4CB6-80B6-97998D5A9506 Q28250508-DFFCAD90-60E7-4D4A-9291-74D7CC8E5CB7 Q28576367-1EA9F893-5D27-4BD3-89F1-A6FB12A470C2 Q30525550-EEC27BD1-7A8D-4E31-A078-BF6BDFD645C3 Q30667424-A8C9EC26-01B0-4859-8540-FB8D840C31B8 Q33666297-953477DB-65CD-4B9A-8E8B-1667198F0BE0 Q33708946-EDD71D3E-358B-4BF6-8B49-3F41EE0F100E Q33797449-72731C7D-6215-4B25-B945-4907B7027CF4 Q33817921-51F21EFD-7663-42DF-A148-2E8216E94CBB Q33878926-FCFC0D5F-5448-4CE9-A8DE-07E9C982F997 Q33980640-4CC76299-37ED-4E4E-943E-91F64F1C1512 Q34062509-1B315D17-D3CD-4335-AE16-CC30A1CC7572 Q34113712-080F303C-4287-4607-9AAE-0F3B674F0BCB Q34146349-97A1F77E-BB3B-4C97-88B1-70F02C922D6B Q34292532-39388A1D-EFB5-4281-A938-445D6A1F9FFE Q34318017-7380623C-5E50-4559-B7C0-797FE55F711D Q34348591-6697776E-88B6-4A6F-8341-9045B3D830EB Q34581042-F6AA5E94-E607-484B-BC9A-0C0FB32C1642 Q34704153-90934997-48C4-46E9-8A88-02BA0C459836 Q34917354-398CA22E-9F5D-4BCE-B6BA-D87522D0D8C5 Q35000764-0D5C1408-983F-4353-AD04-B506E752A074 Q35001040-BAC4CF08-FB26-410C-BF6D-3F7C8F12F145 Q35106542-B42BFB25-F9C5-4885-96A3-B77AC0323940 Q35163459-F8AC3B1D-F561-4F79-B7BC-79D1EB1B47CA Q36149449-5E76F206-FDBF-4DB0-87A4-A2953707A9AC Q36492769-3C87A949-2CCC-4965-9194-20AEC0FBD091 Q36639646-036F522D-7581-4985-B0A1-FF23DD5B839F Q36900126-9B1F6F30-6A70-4845-99D0-7BDFBE3013B4 Q37228718-C120C498-0880-4406-8E2B-79A465CA8B03 Q37272860-C7996279-DE36-47A3-B258-1F477644549C Q37603383-730CF366-CD38-4B3D-B547-7319C8770192 Q37717851-8F1713AA-076A-402E-9AEF-92A28091FED8 Q37955871-CF3DEB7D-123E-45AF-A85B-5F9D264859E1 Q37969262-54CCBAF8-445F-4BEF-91AE-5EFAAEDAFFF8

P2860

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

http://www.wikidata.org/entity/Q34069284

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Elevated tauopathy and alpha-s ...... ains with and without dementia

@ast

Elevated tauopathy and alpha-s ...... ains with and without dementia

@en

Elevated tauopathy and alpha-s ...... ains with and without dementia

@nl

type

label

Elevated tauopathy and alpha-s ...... ains with and without dementia

@ast

Elevated tauopathy and alpha-s ...... ains with and without dementia

@en

Elevated tauopathy and alpha-s ...... ains with and without dementia

@nl

prefLabel

Elevated tauopathy and alpha-s ...... ains with and without dementia

@ast

Elevated tauopathy and alpha-s ...... ains with and without dementia

@en

Elevated tauopathy and alpha-s ...... ains with and without dementia

@nl

P1433

Q34069284-CB6559FA-1D34-4BC4-A49F-2B38DD5B9C37

P1476

Q34069284-60C49ED7-3D54-4BC9-8721-7C5F8B5EC07B

P2093

Q34069284-2B36AE21-B6EC-43C9-831C-92F9896CE7C8

Q34069284-70A8918F-E90C-43A5-B97E-8530BF46A841

Q34069284-7F7CF421-0672-45C0-BF64-E63ED41523B1

Q34069284-D8FDF7DC-72BF-40E9-86EA-28BE7614ADCC

Q34069284-DA63E52A-F3C0-4D01-87A8-E4F3EF8CFB98

Q34069284-F1586720-F8EE-4377-A407-AB242D1874CE

P2860

Q34069284-11FE6D99-B511-4862-AE72-511F0C9E7800

Q34069284-1A73680B-D66A-4BA0-8AC3-115FAABF122C

Q34069284-226987BB-C58D-46F8-9FC4-CF7503AF48D6

Q34069284-23775DA2-7F21-48B8-892A-75EE228C489C

Q34069284-256618FB-5819-4182-A13E-846E53E00C80

Q34069284-269980D8-2A2F-4AF1-B996-4CAD119AA940

Q34069284-287CF648-35CB-4586-A483-FD349D4F1DAF

Q34069284-2B0046B3-73E1-421E-8DD5-B2ECEA12771F

Q34069284-2B3B1833-7AAE-40CE-9639-82E3C982E30A

Q34069284-2EAEF7B6-7688-4024-829F-D3CDEB8AE466

P304

Q34069284-77BCB257-10B9-4BB1-995B-A275CAFC1B2A

P31

Q34069284-C5262C84-9EEE-4B32-9A3C-549BC9F02D77

P356

Q34069284-3FB7C68B-2D04-4819-B765-2C8CE3B89309

P407

Q34069284-0B2C0028-FB9C-4B2B-B4AC-7DD807E5FEF8

P433

Q34069284-728DB98A-7677-4EC1-ABB2-FB2D58EEC804

P478

Q34069284-07C00EC1-E264-4464-A7CB-2EB22A17832E

P577

Q34069284-D78E1E7C-6E13-40E2-B16A-1C67ABD08C87

P5875

Q34069284-A7829313-C4A9-4EE1-A96D-C94D7976499C

P698

Q34069284-AC2C7990-95AC-44D2-B95C-9692F5050234

P921

Q34069284-2FB38DCD-FD10-4CD2-96D1-AD20D7BE3C32

Q34069284-2da23406-f467-4466-b443-edb4d3e9820e

Q34069284-46EF806A-37DD-437D-A356-C548E3CE1203

Q34069284-602A59D1-A22A-4E3B-8AD3-5089FF9E153E

P932

Q34069284-BAAE6D19-2FFE-46A1-93FE-D607E9434639

P356

J.EXPNEUROL.2010.06.017

P1433

Experimental Neurology

P1476

Elevated tauopathy and alpha-s ...... ains with and without dementia

@en

P2093

Anita Sidhu

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Joyce

http://www.w3.org/2001/XMLSchema#string

Jessica Jones

http://www.w3.org/2001/XMLSchema#string

Jonathan Wills

http://www.w3.org/2001/XMLSchema#string

Thomas Haggerty

http://www.w3.org/2001/XMLSchema#string

Valeriy Duka

http://www.w3.org/2001/XMLSchema#string

P2860

Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein

Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

GSK3B polymorphisms alter transcription and splicing in Parkinson's disease

Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

P304

210-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPNEUROL.2010.06.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

225

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45091096

http://www.w3.org/2001/XMLSchema#string

P698

20599975

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2922478

http://www.w3.org/2001/XMLSchema#string